Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.

Sirivichayakul C, Barranco-Santana EA, Esquilin-Rivera I, Oh HM, Raanan M, Sariol CA, Shek LP, Simasathien S, Smith MK, Velez ID, Wallace D, Gordon GS, Stinchcomb DT. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study. J Infect Dis. 2016 May 15; 213(10):1562-72.

View in: PubMed

subject areas

Adolescent
Adult
Antibodies, Neutralizing
Antibodies, Viral
Child
Child, Preschool
Colombia
Dengue
Dengue Vaccines
Dengue Virus
Double-Blind Method
Female
Humans
Infant
Injections, Subcutaneous
Male
Middle Aged
Puerto Rico
Safety
Singapore
Thailand
Vaccines, Attenuated
Young Adult

authors with profiles

Carlos A. Sariol, M.D.

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support